Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)

Inclusion Criteria: * Patients who are converted to Graceptor® from cyclosporine in the maintenance phase after kidney transplantation. * Patients who meet one or more of following criteria 1. Decrease in kidney function: GFR (or eGFR) less than 60 mL/min, or investigator's decision 2. Hypertension: systolic/diastolic blood pressure 130/80 mmHg or more or treatment with an antihypertensive drug 3. Hyperlipidaemia: LDL cholesterol 120 mg/dL or more, or treatment with an antihyperlipidemic drug 4. Rejection: antibody mediated rejection by Banff classification borderline changes or more severe, or investigator's decision 5. Other adverse events and patients who cannot continue cyclosporine treatment based on investigator's decision